Collectively, our data highlighted the essential glycolysis‐related signal axis TMEM161B‐AS1/miR‐23a‐3p/HIF1AN that reprograms ESCC glucose metabolism, and thus, targeting this signal axis may be a promising strategy for the treatment of ESCC patients. The gene discussed is TMEM161B; the disease is esophageal squamous cell carcinoma.